RYTM Pamela J Cramer sells $478K worth of shares
Jun 11, 2025, 4:36 AM
0.00%
What does RYTM do
Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
Pamela J Cramer sold 7,031 shares of RYTM on 6 June at $68.05 per share, worth a total of $478K. They now own 19,209 RYTM shares, or a 27% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.